Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Shares Outstanding (2019 - 2025)

Maxcyte (MXCT) has disclosed Shares Outstanding for 7 consecutive years, with $106.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.02% to $106.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.8 million through Dec 2025, up 1.02% year-over-year, with the annual reading at $106.8 million for FY2025, 1.02% up from the prior year.
  • Shares Outstanding for Q4 2025 was $106.8 million at Maxcyte, roughly flat from $106.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $106.8 million in Q4 2025, with the low at $84.7 million in Q2 2021.
  • Average Shares Outstanding over 5 years is $102.8 million, with a median of $103.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding surged 30.78% in 2021, then grew 1.02% in 2025.
  • Over 5 years, Shares Outstanding stood at $101.2 million in 2021, then rose by 1.18% to $102.4 million in 2022, then grew by 1.53% to $104.0 million in 2023, then increased by 1.68% to $105.7 million in 2024, then rose by 1.02% to $106.8 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $106.8 million, $106.6 million, and $106.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.